Results 211 to 220 of about 118,382 (307)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Opioid-Free Anesthesia Alleviates Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: Study Protocol for a Randomized, Controlled Trial. [PDF]

J Pain Res
Li Y, Hao D, Qi X, Song B.
europepmc   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Sedation and analgesia strategies in the neuro intensive care unit. [PDF]

World J Crit Care Med
Merhavy ZI, Raeburn T, Torres-Ayala GM, McCulloch MA, Varkey TC.   +4 more
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Mechanism of the analgesic effect of electroacupuncture on bone cancer pain through the neuro-immune system: progress based on animal experiments. [PDF]

Front Neurol
Qi P, Zhou M, Han W, Li H, Min L, Li J, Sun Z, Yin H.   +7 more
europepmc   +1 more source

Evaluating the optimal duration of medication treatment for opioid use disorder

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
wiley   +1 more source

Intranasal naloxone to treat suspected synthetic cannabinoid overdose: A case report and literature review. [PDF]

Ment Health Clin
Dickinson J, Buckley T.
europepmc   +1 more source

Characteristics of methamphetamine‐related deaths in the United Kingdom, 1997–2024

Addiction, EarlyView.
Abstract Background and aims People who use methamphetamine have a standardised mortality ratio 6.8 times greater than the general population, with several countries reporting concerning increases in methamphetamine‐related mortality over the past decade.
Emmert Roberts, Rebecca McKetin, Caroline Copeland   +2 more
wiley   +1 more source

The Unregulated Rise of Kratom Drinks: Emerging Challenges and Policy Recommendations. [PDF]

Public Health Rep
Perry T, Chin S.
europepmc   +1 more source